NCT06414733View on ClinicalTrials.gov

HER-2 B Cell Peptide Vaccine

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Metastatic Breast CancerMetastatic Gastrointestinal CarcinomaHER2-positive Breast CancerHER2-positive Gastric CancerEGFR Overexpression
Interventions
BIOLOGICAL

Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720

Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.

Trial Locations (1)

46202

RECRUITING

Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis

All Listed Sponsors
lead

Pravin T.P Kaumaya

OTHER